276. 軟骨無形成症
[臨床試験数:37,薬物数:29(DrugBank:6),標的遺伝子数:4,標的パスウェイ数:25

Searched query = "Achondroplasia"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
3 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2020-001189-13-DK
(EUCTR)
22/12/202007/10/2020Phase 2 study of safety, tolerability, PK and efficacy of recifercept in achondroplasiaA PHASE 2 MULTIPLE DOSE, RANDOMIZED STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND EFFICACY OF RECIFERCEPT IN CHILDREN WITH ACHONDROPLASIA Achondroplasia
MedDRA version: 20.0;Level: LLT;Classification code 10000452;Term: Achondroplasia;System Organ Class: 100000004850;Therapeutic area: Body processes [G] - Bones and nerves physological processes [G11]
Product Name: Recifercept (proposed INN)
Product Code: PF-07256472
INN or Proposed INN: Recifercept (proposed INN)
Other descriptive name: TA-46
Pfizer Inc., 235 East 42nd Street, New York, NY 10017NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
63Phase 2Portugal;United States;Spain;Belgium;Australia;Denmark;United Kingdom;Italy;Japan
2NCT04638153
(ClinicalTrials.gov)
December 2, 202015/9/2020A Study Of Safety, Tolerability And Effectiveness Of Reciferecept In Children With AchondroplasiaA PHASE 2 MULTIPLE DOSE, RANDOMIZED STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND EFFICACY OF RECIFERCEPT IN CHILDREN WITH ACHONDROPLASIAAchondroplasiaBiological: ReciferceptPfizerNULLRecruiting3 Months10 YearsAll63Phase 2Belgium;Spain
3EUCTR2020-001189-13-PT
(EUCTR)
29/09/2020Phase 2 study of safety, tolerability, PK and efficacy of recifercept in achondroplasiaA PHASE 2 MULTIPLE DOSE, RANDOMIZED STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND EFFICACY OF RECIFERCEPT IN CHILDREN WITH ACHONDROPLASIA Achondroplasia
MedDRA version: 20.0;Level: LLT;Classification code 10000452;Term: Achondroplasia;System Organ Class: 100000004850;Therapeutic area: Body processes [G] - Bones and nerves physological processes [G11]
Product Name: Recifercept (proposed INN)
Product Code: PF-07256472
INN or Proposed INN: Recifercept (proposed INN)
Other descriptive name: TA-46
Pfizer Inc.NULLNAFemale: yes
Male: yes
63Phase 2United States;Portugal;Canada;Spain;Belgium;Denmark;Australia;United Kingdom;Japan;Italy